Havemeyer Place LP Purchases Shares of 7,204 Cencora, Inc. $COR

Havemeyer Place LP purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 7,204 shares of the company’s stock, valued at approximately $2,433,000.

Other hedge funds have also added to or reduced their stakes in the company. Oakworth Capital Inc. acquired a new stake in Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new position in Cencora during the 4th quarter worth $27,000. Archer Investment Corp increased its position in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. Optima Capital LLC bought a new position in Cencora during the 4th quarter worth $31,000. Finally, Basepoint Wealth LLC bought a new position in Cencora during the 4th quarter worth $32,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Wells Fargo & Company lowered their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Finally, Citigroup lowered their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Stock Up 1.7%

Shares of NYSE COR opened at $274.94 on Friday. The stock has a market capitalization of $53.49 billion, a P/E ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59. The stock’s fifty day moving average is $292.70 and its 200 day moving average is $330.55. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora declared that its board has approved a share buyback plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.